120 related articles for article (PubMed ID: 20087881)
1. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
Cillessen SA; Meijer CJ; Notoya M; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2010 Apr; 220(5):509-20. PubMed ID: 20087881
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
[TBL] [Abstract][Full Text] [Related]
3. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.
Muris JJ; Ylstra B; Cillessen SA; Ossenkoppele GJ; Kluin-Nelemans JC; Eijk PP; Nota B; Tijssen M; de Boer WP; van de Wiel M; van den Ijssel PR; Jansen P; de Bruin PC; van Krieken JH; Meijer GA; Meijer CJ; Oudejans JJ
Br J Haematol; 2007 Jan; 136(1):38-47. PubMed ID: 17062006
[TBL] [Abstract][Full Text] [Related]
4. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay.
Cillessen SA; Meijer CJ; Ossenkoppele GJ; Castricum KC; Westra AH; Niesten P; Muris JJ; Nijdam HF; van der Hem KG; Flens M; Hooijberg E; Oudejans JJ
Br J Haematol; 2006 Aug; 134(3):283-93. PubMed ID: 16848771
[TBL] [Abstract][Full Text] [Related]
5. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.
Linderoth J; Edén P; Ehinger M; Valcich J; Jerkeman M; Bendahl PO; Berglund M; Enblad G; Erlanson M; Roos G; Cavallin-Ståhl E
Br J Haematol; 2008 May; 141(4):423-32. PubMed ID: 18419622
[TBL] [Abstract][Full Text] [Related]
6. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
8. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.
Uckun FM; Qazi S; Ozer Z; Garner AL; Pitt J; Ma H; Janda KD
Br J Haematol; 2011 Jun; 153(6):741-52. PubMed ID: 21517817
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma.
Muris JJ; Meijer CJ; Ossenkoppele GJ; Vos W; Oudejans JJ
Hematol Oncol; 2006 Sep; 24(3):97-104. PubMed ID: 16715473
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
11. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
[TBL] [Abstract][Full Text] [Related]
12. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in diffuse large B-cell lymphoma.
Wilson WH
Semin Hematol; 2006 Oct; 43(4):230-9. PubMed ID: 17027657
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death.
Hollmann CA; Owens T; Nalbantoglu J; Hudson TJ; Sladek R
Cancer Res; 2006 Apr; 66(7):3550-7. PubMed ID: 16585179
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
Shipp MA; Ross KN; Tamayo P; Weng AP; Kutok JL; Aguiar RC; Gaasenbeek M; Angelo M; Reich M; Pinkus GS; Ray TS; Koval MA; Last KW; Norton A; Lister TA; Mesirov J; Neuberg DS; Lander ES; Aster JC; Golub TR
Nat Med; 2002 Jan; 8(1):68-74. PubMed ID: 11786909
[TBL] [Abstract][Full Text] [Related]
19. B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Papoudou-Bai A; Kitsoulis P; Kanavaros P
Anticancer Res; 2005; 25(1A):347-62. PubMed ID: 15816558
[TBL] [Abstract][Full Text] [Related]
20. Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma.
van Galen JC; Hoefnagel JJ; Vermeer MH; Willemze R; Dijkman R; Tensen CP; de Boer WP; Meijer CJ; Oudejans JJ
J Pathol; 2008 Jul; 215(3):340-6. PubMed ID: 18498125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
